The osteoinduction of C2C12 myoblast cell-line treated with growth factor-incorporated biocomposites

Abstract

Bone regeneration scaffold serves as an alternative treatment to critical bone defects, substituting the traditional gold standard autologous bone grafting. A number of biomaterials and osteogenic growth factors are of the scientists’ interest in developing this bone scaffolds, to satisfy the required characteristics including having the osteoconductive and osteoinductive features. FDA-approved treatments are known as Medtronic InfuseTM rhBMP-2 and Stryker OsigraftTM rhBMP-7, where both are osteogenic proteins. However, Infuse TM was shown to induce ectopic bone growth, while OsigraftTM was unable to prove its effectiveness in treating non-unions, thus being discontinued from the market. This research is interested in comparing the use of an alternative active pharmaceutical ingredients (API) to have a comparable osteogenic performance to the protein, since it is advantageous in terms of greater conformational control, giving higher stability over cellular interactions